NASDAQ · LH
Healthcare · Medical - Equipment & Services
$312.15
Down-$2.05 (-0.65%)
Updated Oct 11, 2026, 1:05 PM
SID Score
7.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance · LH
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
LH closed at $312.15 after 20 trading sessions, down 1.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $313.39 | $318.175 | $311.62 | $312.15 | 607.87K |
| Oct 8, 2026 | $312.34 | $315.48 | $309.04 | $314.20 | 703.73K |
| Oct 7, 2026 | $312.04 | $315.085 | $311.21 | $311.97 | 546.62K |
| Oct 6, 2026 | $310.41 | $312.7551 | $304.92 | $311.71 | 987.79K |
| Oct 5, 2026 | $308.08 | $309.785 | $305.84 | $308.65 | 705.91K |
| Oct 2, 2026 | $305.77 | $309.36 | $302.71 | $308.49 | 588.22K |
| Oct 1, 2026 | $306.00 | $309.72 | $304.06 | $304.60 | 559.55K |
| Sep 30, 2026 | $311.00 | $311.54 | $306.98 | $308.11 | 646.18K |
| Sep 29, 2026 | $306.89 | $309.95 | $306.58 | $308.81 | 613.11K |
| Sep 28, 2026 | $306.85 | $312.57 | $306.85 | $309.57 | 782.48K |
| Sep 25, 2026 | $308.24 | $312.30 | $306.5471 | $309.64 | 821.53K |
| Sep 24, 2026 | $304.62 | $309.54 | $303.13 | $308.95 | 784.94K |
| Sep 23, 2026 | $311.91 | $312.82 | $303.50 | $303.98 | 909.6K |
| Sep 22, 2026 | $303.46 | $316.529 | $303.46 | $311.54 | 1.91M |
| Sep 21, 2026 | $321.95 | $323.84 | $318.94 | $320.99 | 487.76K |
| Sep 18, 2026 | $322.00 | $322.70 | $319.38 | $320.71 | 1.74M |
| Sep 17, 2026 | $326.79 | $326.79 | $321.40 | $322.73 | 559.88K |
| Sep 16, 2026 | $323.51 | $325.30 | $320.38 | $324.51 | 561.4K |
| Sep 15, 2026 | $314.09 | $327.95 | $309.63 | $323.97 | 878.29K |
| Sep 14, 2026 | $314.12 | $316.485 | $308.21 | $315.31 | 707.84K |
The latest Smart Investors Daily articles mentioning LH.
Company
Market Activity
Research & News
LH research
Company profile and research snapshot.
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | Truist Securities | Buy | — |
| Sep 11, 2026 | UBS | Buy | — |
| Sep 11, 2026 | Barclays | Equal-Weight | — |
| Aug 4, 2026 | Piper Sandler | Neutral | — |
| Aug 3, 2026 | JP Morgan | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 8, 2026
Labcorp Holdings is slated to report its third-quarter earnings later this month, and Wall Street expects its profit to rise at a lower-double-digit rate from a year ago.
SeekingAlpha · Oct 7, 2026
Natera is rated Sell, as its valuation is stretched, with perfect execution priced in, despite looming competitive threats. Click to read more about NTRA.
Yahoo · Oct 5, 2026
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced investors.
Yahoo · Sep 30, 2026
Danaher's Biotechnology segment posts 4% sales growth, but tough comparisons and shipment timing could test its momentum.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LH.
